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Abstract
Longer wait times for deceased donor kidney transplant have prompted newer initiatives to
expedite the process. Reuse of a previously transplanted kidney might be appropriate in certain
circumstances. However, one must also consider the unique issues that may arise after such
transplants. We describe our experience in one such case where the donor kidney had lesions of
focal and segmental glomerulosclerosis and signs of alloreactivity (positive C4d staining) prior to
transplantation and the recipient developed ganciclovir-resistant cytomegalovirus (CMV)
infection, which was perhaps transmitted from the donor. Despite the challenges, the allograft
function remained stable 5 years after reuse.
Keywords: cytomegalovirus (CMV); ganciclovir resistance; organ reuse; rejection
Case description
The recipient
A 42-year-old African American male, whose reported
cause of end-stage renal disease (ESRD) was hyperten-
sion, received a one-antigen-matched deceased donor
kidney transplant in June 2005.
The donor(s)
A 38-year Caucasian female (donor B), who developed
ESRD due to type 1 diabetes mellitus, received a living
donor kidney transplant in 1997, and a pancreas trans-
plant in 2002. Both organs failed and she subsequently
received a simultaneous kidney-pancreas (SPK) trans-
plant in April 2005. She was at intermediate risk for cyto-
megalovirus (CMV) infection at the time of the SPK
transplant (D−/R+) and her maintenance immunosup-
pression consisted of tacrolimus, mycophenolate mofetil
(MMF) and prednisone. Her records indicated that she
was treated for CMV infection based on symptomatology
(fever and diarrhea) with intravenous ganciclovir about a
month after SPK transplant for an undetermined period
of time followed by prophylaxis with oral valganciclovir at
450 mg/day. Her cause of death was a spontaneous in-
tracranial bleed, and at the time of recovery of her trans-
planted kidney, CMV IgM was not detected in serum. A
frozen section of donor B’s kidney revealed normal renal
parenchyma with only one obsolescent glomerulus of
100 in the sample. However, the ﬁnal interpretation,
communicated 2 days after the transplant, revealed focal
and segmental glomerulosclerosis (FSGS), with collapsing
features, diffuse C4d staining in the peritubular capillaries
(Figure 2D) and acute tubular necrosis suggestive of
acute humoral rejection. Electron microscopy (EM) re-
vealed diffuse podocyte foot process effacement.
The original donor (donor A) was an 18-year-old
African American male who had died due to blunt force
trauma to the head causing an intracranial bleed.
We proceeded with the transplant based on the frozen
section ﬁndings, terminal creatinine value (1.2 mg/dL)
and the total cold ischemia time (27 h and 22 min). Our
patient received induction therapy with anti-rabbit thy-
mocyte globulin (ATG) and methylprednisolone; intrave-
nous ganciclovir was used as prophylaxis against the
CMV since he had delayed graft function and was receiv-
ing ATG. Since the renal allograft had lesions of FSGS, the
urine protein-to-creatinine ratio (U P/Cr) was monitored,
and the initial ratio was 2.8. ATG was continued for 2
weeks and ganciclovir for 3 weeks (0.625 mg/kg three
times a week for 2 weeks followed by 0.625 mg/kg/day
for 1 week) after which he received oral valganciclovir
450 mg/day (adjusted to glomerular ﬁltration rate, GFR).
Serum creatinine decreased from 13.9 to 3.5 mg/dL on
day 13 post transplant, at which point dialysis treatments
were stopped and immunosuppression was maintained
with tacrolimus, MMF and prednisone.
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On day 24 post transplant, his white blood cell count
decreased to 2400 cells/mm3, which led to the lowering
of the MMF (from 2000 mg to 1000 mg/day). The leuko-
penia persisted for another week and his blood tested
positive for CMV DNA by PCR (307 000 copies/mL) at
which point MMF was discontinued and intravenous
ganciclovir at 2.5 mg/kg/day was substituted for oral
valganciclovir. He then became symptomatic with fever
and malaise and the CMV levels in the blood rose to
1 199 000 copies/mL over a 2-week period despite ade-
quate doses of ganciclovir. The possibility of mutant CMV
strain resistant to ganciclovir was considered and intrave-
nous foscarnet 3 g every 12 h (50 mg/kg every 12 h for
estimated GFR of 58 mL/min) was started. His symptoms
improved quickly and as depicted in Figure 1, CMV
decreased dramatically over the next 2 weeks to 3000
copies/mL. A mutation for ganciclovir resistance tested
positive at the UL-97 location. On day 75 post transplant,
CMV was no longer detectable in his blood. Foscarnet
was continued for a total of 3 months, his tacrolimus
level during this episode was 5–8 ng/mL and the U P/Cr
ranged between 1.25 and 2.5. His maintenance immuno-
suppression was changed to tacrolimus, leﬂunomide and
prednisone.
A biopsy performed on day 110 post transplant re-
vealed persistent lesions of FSGS (EM revealed only focal
foot process effacement) and diffuse C4d staining in the
peritubular capillaries (Figure 2A and E). Since the donor-
speciﬁc antibodies (DSA) tested negative, no treatment
was initiated. A second allograft biopsy at 5.5 months
post transplant still revealed FSGS and only focal C4d
staining.
Over the next year, CMV DNA was monitored monthly
and was not detected. Another biopsy performed 13
months post transplant still revealed FSGS lesions
(Figure 2C), but C4d staining was negative. However,
tubular atrophy increased to ∼40%. The U P/Cr was 0.6–
0.8 and the serum creatinine level was 1.6–2.0 mg/dL. At
last follow-up, 5 years after transplant, his serum creati-
nine level was 2.1 mg/dL, with a U P/Cr (obtained several
months earlier) of 0.12. The clinical course of our patient
is depicted in Figure 1.
Discussion
The average wait time to receive a deceased donor kidney
transplant in the USA is 4–5 years [1, 2]. Under appropri-
ate circumstances, expanded criteria donors [3], donation
after cardiac death donors [4], donors with hepatitis C [5]
and CDC (Centers for Disease Control and Prevention)
high-risk donors [6] are considered. Today, the most
common cause of loss of the renal allograft is death of
the patient with a functioning graft. Ojo et al. analyzed
data registered with the Scientiﬁc Registry of Transplant
Recipients between 1987 and 1996 and found that 43%
of the kidney transplant recipients at the time of death
had a creatinine value of 1.9 ± 0.8 mg/dL, which com-
pared favorably with recipients that were alive with a
functioning graft and had a creatinine value of 1.7 ± 0.7
mg/dL [7].
Three case reports of kidney reuse are reported in the
literature [8–10], without any major issues. Recently, a
fourth report regarding the reuse of the kidney allograft
was described where the EM lesions of FSGS in the
primary recipient disappeared after it was transplanted
into another recipient without underlying FSGS [11]. Both
allograft function and EM changes improved after the
second transplant. It is important to note that the glo-
meruli did not reveal light microscopic changes of FSGS.
Our case is exceptional in that the patient, despite re-
ceiving a reused organ, overcame all odds to eventually
have a great outcome. Although our case was a success
story, it came at a price. It not only presented us with
unique challenges but also added additional costs to the
health system.
First, CMV infection was encountered early after trans-
plantation and increase in CMV viremia in the presence
of adequate doses of ganciclovir led us to consider
Fig. 1. Timeline of clinical events after transplantation. As noted in the ﬁgure, CMV decreased dramatically after starting foscarnet. Also noted in the
ﬁgure are the serum creatinine values, tacrolimus levels and urine protein-to-creatinine ratios.
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ganciclovir resistance [12]. It was mentioned that donor B
was treated for CMV infection with intravenous ganciclovir
after the SPK transplant and was then placed on a pro-
phylactic dose of valganciclovir 450 mg/day in the pres-
ence of normal allograft function. Our conjecture is that
sub-therapeutic valganciclovir dose in the presence of
sub-clinical CMV infection or low levels of viremia might
have predisposed to ganciclovir resistance. The mutant
CMV strain was transmitted to our patient through donor
B as our patient was never exposed to ganciclovir.
Next, the C4d staining in the donor kidney was most
likely due to humoral alloreactivity in donor B against
donor A alloantigens. Our patient was not sensitized prior
to transplantation and the crossmatch testing was nega-
tive, and there were no light microscopic features of anti-
body-mediated rejection or the presence of donor-speciﬁc
antibodies. Also, data from protocol biopsies in sensitized
transplant recipients [13] and other longitudinal renal al-
lograft biopsy studies [14] suggest that C4d staining could
persist for several months. This could explain the possi-
bility that in our patient, C4d was detected when the
biopsy was performed on day 110 post transplant and at
5.5 months, but was not detected after 13 months.
Lastly, the lesions of FSGS with foot process effacement
came from the donor kidney (donor B). It is unknown
whether these lesions could have been transmitted
through donor A as there was no pre-implantation biopsy.
To the best of our knowledge, our patient had ESRD due
to hypertension. After transplantation, we carefully moni-
tored the U P/Cr and while the repeat biopsies revealed
persistence of the FSGS lesions, there was some resolution
of the foot process effacement (diffuse to focal). The key
difference in our case compared with the recent report
[11] was the presence of established light microscopic
lesions of FSGS at the time of transplantation and hence,
we are unsure whether these lesions would resolve.
In conclusion, organ reuse seems worth the effort.
Perhaps, with caution, it could be explored on a larger
scale. However, such an effort needs coordination amongst
transplant centers, organ-procuring organizations and
regulatory bodies to come up with a plan. While the task
certainly seems daunting, a discussion seems worthwhile.
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